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Mutations in noncoding regions of GJB1
are a major cause of X-linked CMT
ABSTRACT
Objective: To determine the prevalence and clinical and genetic characteristics of patients with X-
linked Charcot-Marie-Tooth disease (CMT) due to mutations in noncoding regions of the gap junc-
tion b-1 gene (GJB1).
Methods: Mutations were identified by bidirectional Sanger sequence analysis of the 595 bases
of the upstream promoter region, and 25 bases of the 39 untranslated region (UTR) sequence in
patients in whommutations in the coding region had been excluded. Clinical and neurophysiologic
data were retrospectively collected.
Results: Five mutations were detected in 25 individuals from 10 kindreds representing 11.4% of
all cases of CMTX1 diagnosed in our neurogenetics laboratory between 1996 and 2016. Four
pathogenic mutations, c.-17G.A, c.-1711G.T, c.-103C.T, and c.-146-90_146-89insT were
detected in the 59UTR. A novel mutation, c.*15C.T, was detected in the 39 UTR of GJB1 in 2
unrelated families with CMTX1 and is the first pathogenic mutation in the 39UTR of any myelin-
associated CMT gene. Mutations segregated with the phenotype, were at sites predicted to be
pathogenic, and were not present in the normal population.
Conclusions: Mutations in noncoding DNA are a major cause of CMTX1 and highlight the impor-
tance of mutations in noncoding DNA in human disease. Next-generation sequencing platforms
for use in inherited neuropathy should therefore include coverage of these regions. Neurology®
2017;88:1445–1453
GLOSSARY
CMT 5 Charcot-Marie-Tooth disease; CMTX 5 X-linked Charcot-Marie-Tooth disease; CV 5 conduction velocity; Cx32 5
connexin 32; EVS 5 Exome Sequencing Project; ExAC 5 Exome Aggregation Consortium; GJB1 5 gap junction b-1 gene;
IRES 5 internal ribosomal entry site; ORF 5 open reading frame; UTR 5 untranslated region.
Mutations in the gap junction b-1 gene (GJB1) encoding the transmembrane channel protein,
connexin 32 (Cx32), are the most common cause of X-linked Charcot-Marie-Tooth disease
(CMTX) and the second commonest cause of Charcot-Marie-Tooth disease (CMT) overall.1
The Cx32 protein is widely expressed in human tissues, including myelinating Schwann cells in
the peripheral nervous system.2 In the peripheral nervous system, Cx32 is found in the non-
compact myelin of the paranodes and incisures, where it allows the movement of small mole-
cules and ions between the multiple concentric myelinated layers of the Schwann cell and the
axon membrane.2,3 GJB1 exists as 2 transcripts that are regulated by 2 tissue-specific promoters
(P1 and P2), allowing differential expression of these transcripts in neuronal and non-neuronal
tissue.4–6 The transcriptional machinery in neuronal tissue requires the P2 promoter and other
elements located in the 59 untranslated region (UTR) for efficient Cx32 expression. Mutations
in the 59 UTR region have previously been described by our group and others as causative of
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CMTX1 and have been shown to impair P2-
mediated transcription ofGJB1.7 Mutations in
the 39 UTR region are a rare cause of heredi-
tary diseases overall; however, as this region
often contains mRNA regulatory elements,
mutations in the 39 UTR may affect normal
translation.8 In this study, we sought to deter-
mine the frequency and phenotype of
CMTX1 due to mutations in the 59 and 39
UTR noncoding regions of GJB1.
METHODS Patients. Patients harboring mutations in the 59
and 39 UTR of GJB1 were identified from the CMT database of
the National Hospital for Neurology and Neurosurgery, Queen
Square, London, United Kingdom. In some patients in whom
Sanger sequencing of the coding region of GJB1 was negative,
further screening of the 59 and 39 UTR was performed because of
the strong clinical suspicion of CMT1X on the basis of a lack of
male-to-male transmission, more severely affected males, and
a predominantly demyelinating polyneuropathy. The remaining
patients were identified from diagnostic samples submitted for
testing of GJB1 to the neurogenetics laboratory of The National
Hospital of Neurology and Neurosurgery after routine screening
of both the coding and noncoding regions of GJB1 was adopted.
The clinical and neurophysiologic data were collected
retrospectively for all identified patients with mutations in the
59 and 39 UTR of GJB1.
Statistical analysis. Statistical analysis was performed using a 2-
tailed Student unpaired t test (Excel; Microsoft, Redmond, WA).
Genetics analysis. Genetic testing was performed in the
National Hospital of Neurology and Neurosurgery
Neurogenetics Laboratory. Additional targeted genetic testing
was performed in selected cases (appendix e-1 at Neurology.
org). Mutations were identified by bidirectional Sanger
sequence analysis of GJB1 including 595 bases upstream of the
ATG start codon, the coding region, and 25 bases of 39 UTR
Figure 1 Pedigrees for the families reported in this study
Black symbols 5 affected; empty symbols 5 unaffected; dot symbols 5 affected by history; diagonal line 5 deceased; arrow 5 index case.
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Table 1 Clinical features of patients with X-linked Charcot-Marie-Tooth disease due to mutations in the 59 and 39 untranslated regions of GJB1
ID Mutation Sex
Age at
onset, y
Age at
evaluation,
y
Presenting
symptom
Split
hand
APB/
FDIO/
ADM
Ankle
dorsiflexion/
plantar flexion Reflexes UL/LL Plantars Pinprick UL/LL Vibration UL/LL Other CMTES
1-I.2 c.-17G.A F 55 61 Unsteadiness No 5/41/5 41/5 Present/ankles absent [/Y N/299 below
knee
N/knee Pain, deafness left ear,
Horner syndrome, CSF
protein 0.49, abnormal
MRI
13
1-II.2 c.-17G.A F 22 42 Unsteadiness No 4/4/42 41/5 Brisk/knees brisk and
ankles absent
Mute Mid-forearm/
mid-calf
N/CM Pain, scoliosis, Raynaud
disease, normal MRI
14
1-II.4 c.-17G.A F 30 45 Difficulty walking Yes 3/2/42 1/4 Brisk/ankles absent Mute Wrist/mid-calf N/knee Scoliosis, pain 10
1-III.3 c.-17G.A M 8 24 Tremor and
difficulty writing
Yes 42/42/4 2/5 Triceps reduced, biceps
and supinator absent/
knees reduced and
ankles absent
Y/Y N/N N/N Tremor, pain 7
1-III.5 c.-17G.A F 15 25 Difficulty walking
and leg pain
No 42/42/4 4/5 Present/ankles absent Y/Y N/N N/N Tremor, pain 5
1-IV.2 c.-17G.A F 8 16 Clumsiness and
leg pain
No 5/5/5 5/5 Reduced/ankles absent Y/Y N/N N/N Pain —
2-II.2 c.-17G.A F 58 Asymptomatic No 5/5/5 5/5 Present/present Y/Y N/N N/N — 0
2-III.1 c.-17G.A M 18 33 Difficulty walking Yes 3/4/4 4/5 Present/ankles absent Y/Y N/ankle N/N Tremor 8
2-III.3 c.-17G.A M 26 34 Clumsy hands,
difficulty walking
No 4/41/4 4/5 Present/ankles absent [/Y Mid-forearm/
mid-calf
N/ankle Positive sensory
symptoms, CSF
protein 0.45
10
2-III.4 c.-17G.A M 32 33 “Floppy” walking Yes 3/4/4 2/4 Present/ankles absent Y/Y N/N N/N Normal MRI —
3-III.2 c.-103C.T M ,10 39 Foot drop Yes 0/2/3 0/5 Present/ankles absent Y/Y 299 Above wrist/
below knee
Wrist on right and MCP
on left/ASIS on right
and CM on left
Tremor —
3-III.5 c.-103C.T M 15 37 Clumsiness Yes 2/3/4 1/42 Absent/absent Mute N/mid-foot N/ankle Abnormal MRI 9
4-III.1 c.-17G.A M ,10 34 Frequent falls Yes 1/4/4 3/5 Triceps reduced, biceps
and supinator absent/
ankles absent
Mute N/N N/ankle Tremor, pain 8
4-III.3 c.-17G.A M ,10 32 Difficulty walking Yes 2/4/42 2/5 Present/ankles absent ?/[ N/above ankle N/ankle Tremor 11
4-III.5 c.-17G.A F 31 Asymptomatic
“Family gait”
Yes 4/4/4 4/5 Present/right ankle
reduced and left absent
Y/Y N/mid-foot N/N Tremor 9
5-I.2 c.*15C.T F 58 Asymptomatic No 5/5/5 5/5 Present/present Y/Y N/N N/N — 0
5-II.1 c.*15C.T F 29 Asymptomatic No 5/5/5 5/5 Present/present Y/Y N/N N/N — 0
5-II.2 c.*15C.T M 5 21 Difficulty walking No 42/42/
42
3/5 Absent/ankles absent Y/Y N/N N/N Pain 15
6-III.1 c.-
1711G.T
M 15 35 Difficulty walking Yes 2/4/a 0/5 Supinator absent/
absent
Y/Y N/feet N/knee Normal MRI 13
6-III.2 c.-
1711G.T
M 15 24 Difficulty walking — — — — — — — — —
Continued
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sequence. Conditions and primers are available in appendix e-1.
In silico analysis was performed with the aid of AlamutVisual
(Interactive Biosoftware, Rouen, France), which includes the
splice-prediction tools SpliceSiteFinder-like, MaxEntScan,
NNSPLICE, GeneSplicer, and Human Splicing Finder.
Standard protocol approvals, registrations, and patient
consents. This study was approved by the research ethics com-
mittee of the National Hospital for Neurology and
Neurosurgery. All patients consented to publication of their
clinical details.
RESULTS Demographics. A total of 25 individuals
from 10 kindreds with mutations in the 59 and 39
UTR of GJB1 were identified (figure 1), of whom 14
were male and 11 female. The age at onset was re-
ported to be less than 10 years in 7 male participants
and 1 female participant with a range of 5–32 years in
male participants and 8–55 years in female partici-
pants. Four patients from family 1 (1-I.2, 1-II.2, 1-
II.4, and 1-III.3) and all 4 patients from family 2 have
been reported previously.9 There was no male-to-
male transmission in any of the pedigrees. From
1996 to 2016, 194 patients with mutations in the
open reading frame of GJB1 were identified.
Mutations in the 59 and 39 UTR therefore
represent 11.4% of patients with CMTX1
identified in our neurogenetics laboratory.
Clinical features. The clinical details of the cohort
are summarized in table 1. The most common
presenting complaint was difficulty walking. Male
participants were more severely affected than
female participants. The mean Charcot-Marie-
Tooth Examination Score was 6.30 6 5.31
(range 0–14, n 5 10) for female participants and
11.5 6 3.81 (range 7–18, n 5 10), for male
participants (p 5 0.021). One woman (2-II.2,
aged 58) harboring the c.-17G.A mutation and
3 women (5-I.2, 5-II.1, and 10-III.3, aged 58, 29,
and 71, respectively) harboring the c.*15C.T
mutation were asymptomatic but all had
abnormal nerve conduction studies (table 2).
Atypical presentations in our cohort included the
following: patient 1-I.2 from family 1 (c.-17G.A)
presented with late-onset CMTX (age 55),
unilateral deafness, and Horner syndrome,
characterized by miosis and ptosis. The proband
(1-II.2) had mild scoliosis and her son (1-III.3)
presented at age 8 years with hand tremor and
difficulty writing. Three patients (1-I.2, 2-III.3,
and 4-III.3) from families 1, 2, and 4 harboring
the c.-17G.A mutation had unilateral extensor
plantar responses. Postural tremor was present in
5 out of 6 male participants and 2 out of 7 female
participants harboring the c.-17G.A mutation.
Twelve patients had a split-hand, characterized
by disproportionate involvement of the abductor
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Table 2 Neurophysiologic data
ID Sex
Age at
examination, y
Sensory nerve action potentials Compound muscle action potentials
Median (FIII-W) Ulnar (FV-W) Radial (forearm-W) Sural (calf-ankle) Median SE on APB Ulnar SE on ADM
C peroneal SE on
EDB P tibial SE on AH
Amp, mV
(‡8)
CV, m/s
(‡50)
Amp, mV
(‡5)
CV, m/s
(‡50)
Amp, mV
(‡20)
CV, m/s
(‡50)
Amp, mV
(‡5)
CV, m/s
(‡40)
Amp, mV
(‡5)
CV, m/s
(‡50)
Amp, mV
(‡8)
CV, m/s
(‡50)
Amp, mV
(‡2.5)
CV, m/s
(‡40)
Amp, mV
(‡4)
CV, m/s
(‡40)
1- I.2 F 61 3 43.5 5 50.5 16 55 Abs — 5.8 44 9.5 56 1.1 35 7.4 —
1-II.2 F 45 4 40.5 3 46.5 16 47 Abs — 1.6 32 7.7 51 Abs — 0.6 —
1-II.4 F 41 3 40 5 57 13 46 Abs — 6.2 50 9.1 63 0.2 37 9.1 35
1-III.3 M 25 Abs Abs Abs — Abs — Abs — 0.5 32 7.5 39 Abs Abs 0.9 38
2-II.2 F 58 9.8 50 6.5 57.1 Abs — Abs — 6.7 53.7 11.3 60.3 0.8 43.7 1.5 37.9
2-III.1 M 41 2.6 41.7 3.5 39.1 11 37.6 3 40.5 2.5 35.5 5.7 41.1 0.8 32.9 4.2 35.2
2-III.3 M 34 3 38.5 1 40.5 — — 1 31.5 0.9 42 5.2 42 0.1 23 4.1 35
2-III.4 M 33 2.7 36.7 5.2 40 6 38.5 3 31.4 0.6 34.7 4.1 39.1 0.1 33.5 0.5 27.9
3-III.2 M 39 Abs — Abs — Abs — — — 0.2 23 2.6 33 1 41 — —
3-III.5 M 37 2 38 Abs — 13 48 Abs — 1.5 36 2.5 40 Abs — 0.2 27
4-III.1 M 34 — — — — Abs — Abs — 0.5 — 6.5 — 0.1 27 — —
4-III.3 M 32 Abs — Abs — 5 — — — 1.3 27 3.6 32 Abs — — —
4-III.5 F 31 Abs — Abs — 14 — — — 8.6 48 7.8 38 Abs — — —
5-I.2 F 58 8 47 5 50 16 50 6 41 5.5 58 9.4 57 3.9 46 12 53
5-II.1 F 29 4 50 5 48 20 50 Abs — 5.9 53 10.8 60 6.6 45 12.8 45
5-II.2 M 21 Abs — Abs — Abs — — — 1.9 34 1.4 37 — — 0.6 32
6-III.1 M 30 Abs — Abs — — — Abs — 1.9 32.5 9.3 41.1 Abs — 2.7 34.4
7-III.1 M 48 Abs — Abs — 9 38 Abs — 0.3 — 4.5 36 Abs — — —
8-II.1 M Unknown — — — — — — — — 1.3 30 — — — — — —
9-IV.2 F 30 3 38 3 37 15 43 Abs — 4.8 40 8.3 45 0.1 32 2.4 32
10-III.3 F 71 Abs — Abs — 9 45.5 Abs — 8.1 50 9.3 57 1.9 37 — —
10-IV.3 M 45 Abs — Abs — Abs — Abs — 5.3 38 3.4 35 0.1 22 — —
Abbreviations: — 5 not recorded; Abs 5 absent; ADM 5 abductor digiti minimi; AH 5 abductor hallucis; Amp 5 amplitude; APB 5 abductor pollicis brevis; C 5 common; CV 5 conduction velocity; EDB 5 extensor
digitorum brevis; FIII 5 finger III; ID 5 family/patient identification; P 5 posterior; SE 5 surface electrode; W 5 wrist.
N
eurology
8
8
A
pril1
1
,2
0
1
7
1
4
4
9
pollicis brevis compared with the first dorsal
interosseous and abductor digiti minimi muscles.
Neurophysiology. Nerve conduction studies were
available in 22 individuals (13 male and 9 female)
and in all cases demonstrated a motor and sensory
neuropathy (table 2). In male participants, the mean
ulnar motor nerve conduction velocity (CV) was
37.78 6 3.43 m/s (range 32–42 m/s), whereas in
female participants, the mean ulnar CV was
54.15 6 8.09 m/s (range 38–63 m/s), p , 0.0001
(tables 2 and e-1). There was a discrepancy between
the median and ulnar compound muscle action po-
tentials’ amplitude, with the former being signifi-
cantly reduced compared to the latter (table e-1).
This finding is in accordance with the clinical obser-
vation of the split-hand.10
MRI. Brain MRI was performed in 5 patients (3 male
and 2 female) and revealed a lesion of the corpus cal-
losum in 1 female patient (1-I.2) with no vascular risk
factors or clinical features suggestive of multiple
sclerosis (appendix e-1).
Neuropathology. Sural nerve biopsy was available
from 2 patients (1-II.2 and 2-III.3) and revealed
a significant reduction in myelinated nerve fiber
density and thin myelin sheaths (appendix e-1).
There were occasional regeneration clusters and
mild endoneurial edema. There were no
inflammatory cells. These findings are similar to
coding GJB1 mutation patients.
Genetic analysis. Five distinct mutations in the 59 and
39 UTR of GJB1 were identified (table 1). The posi-
tion of the mutations relative to the GJB1 open read-
ing frame (ORF) region is shown in figure 2. The
nomenclature used in this study is based on current
recommendations of the Human Genome Variation
Society (HGVS).11 In table e-2, there is an overview
of all mutations in the 59 and 39 UTR regions of
GJB1 and the corresponding nomenclature based
on counting directly from the ATG translation initi-
ation codon, which has been previously used to
describe a number of mutations. The previously re-
ported mutations9,12–15 c.-103C.T and c.-17G.A
were detected in 2 (3 and 7) and 4 unrelated families
(1, 2, 4, and 9), respectively, and segregated with the
phenotype in all family members tested. Three novel
mutations were identified: c.-146-90_-146-89insT in
family 8, c.-1711G.T in family 6, and c.*15C.T
in families 5 and 10. The genome conservation scores
are shown in table e-3; they were assessed using
PhiloP, which were accessed through the UCSC
Genome Browser (GRCh37/hg19).16 These 3 novel
mutations segregate with the phenotype and are
predicted to be pathogenic using AlamutVisual
(Interactive Biosoftware) software. They are not
present in the NHLBI Exome Sequencing Project
(EVS), Exome Aggregation Consortium (ExAC),
dbSNP, or the 1000 Genome (1000genomes)
databases.17–20 ExAC and EVS only include the
ORF and 650 bp of intronic sequences. The 2
new variants within the 59 UTR region were not
detected in 100 controls. The new variant in the 39
UTR is not present in ExAC. The scores of the in
silico splicing analysis for c.*15C.T are shown in
table e-4.
DISCUSSION In this study, we describe 2 new
pathogenic mutations in the 59 UTR and a likely
pathogenic mutation in the downstream 39 UTR
region of GJB1. The evidence for the pathogenicity
of these mutations is largely indirect and based on
a typical CMT X1 phenotype, segregation within
family members, in silico splice prediction analysis,
and for the 39 UTR mutation, the presence of the
same mutation in an unrelated individual with the
same phenotype. All patients included in this study
had a clinical or neurophysiologic phenotype typical
for CMTX1 due to mutations in the GJB1 ORF
region, characterized by a slowly progressive, pre-
dominantly length-dependent neuropathy, in
which male participants were more severely
affected than female participants and with an
earlier age at onset.21 In male participants, the
motor CVs were in the intermediate range and
slower than in female participants, as has been
described previously.22 Evidence suggests that loss
of Cx32 channel function is the underlying
pathomechanism responsible for CMTX1 due to
coding mutations in GJB1.23
The nerve-specific 59 UTR of GJB1 is located
immediately upstream of the start codon, adjacent
to the P2 promoter. The P2 promoter contains
binding sites for the neuron-specific transcription
factors SOX10 and EGR2 that strongly activate
Cx32 expression in the peripheral nervous sys-
tem.7,24 EGR2 has 3 proposed binding sites (E1,
E2, and E3) within the P2 promoter, whereas
SOX10 has 2 P2 binding sites (S1 and S2) (figure
2). Several mutations located within the core of the
S2 SOX10 binding site have previously been
described, a number of which have been shown to
impair SOX10-mediated transcription of GJB1, re-
sulting in a significant reduction in Cx32 expres-
sion.7,12,25,26 The novel c.-146-90_-146-89insT
mutation is located within the E3 EGR2 binding
site. The E2 and E3 binding sites of promoter P2
are responsible for the majority of EGR2-mediated
transcriptions of GJB1.24 It is therefore likely that
this mutation results in reduced Cx32 expression as
observed for mutations within the SOX10 binding
site.
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The c.-17G.A mutation was identified in 4 dif-
ferent families (1, 2, 4, and 9) and has previously been
reported by our group.9 This mutation is located in
the last base of exon 1b, which is one of the most
highly conserved bases in splice-site consensus se-
quences. In silico splice site analysis predicted that
this mutation may reduce the efficiency of splicing
at this intron/exon boundary, leading to the inclusion
of intron 1 and a mutant transcript.9 The second
novel c.-1711G.T mutation in family 6 affects
the adjacent base and is predicted to be pathogenic
by the same mechanism.
We identified the c.-103C.T mutation in 2 dif-
ferent families (3 and 7). This mutation has previ-
ously been reported in unrelated families.12,14,15,27 It is
located within exon Ib, downstream of the P2 pro-
moter, and lies within the internal ribosomal entry
site (IRES) of the peripheral nerve specific mRNA
transcript. The mutation is predicted to prevent
translation of GJB1 mRNA.28 Taken together, our
study and previous reports provide strong evidence
that the c.-103C.T is pathogenic. Of note, the
c.-102G.A variant (reported as c.-458G.A), affecting
the adjacent base, did not segregate in a large family
with CMT, suggesting that not every variant of an
IRES element is pathogenic.29
Despite being located in a less conserved region,
the mutation in the 39 UTR region, c.15C.T*, seg-
regated in 2 unrelated families with a typical CMTX1
phenotype. This specific 39 UTR region contains se-
quences that are predicted to act as regulatory ele-
ments critical in Cx32 translational activation/
repression, mRNA stability, micro-RNA binding,
and transcript localization.8 Although our under-
standing of the role of these sequences is poor, in
silico splicing analysis predicts that this variant may
create a 59 donor splice site leading to aberrant splic-
ing within the 39 UTR. This in turn may affect
mRNA stability, leading to downregulation of
GJB1 expression.
The clinical and electrophysiologic findings of the
patients described in this article with point mutations
within S2 SOX10 and E3 EGR2 are indistinguish-
able from patients with mutations in the ORF of
Figure 2 GJB1 gene structure with mutations in noncoding regions highlighted
(A) Structural organization ofGJB1. (B) Base numbering at each junction between regions according to the Human Genome Variation Society. (C)GJB1 has 2
tissue-specific promoters (P1 and P2) that are alternatively spliced. In liver and pancreas, GJB1 transcription is driven via promoter 1 (P1) upstream of the
noncoding exon, exon 1a, whereas in neural tissue it is driven via the nerve-specific promoter 2 (P2) upstream of noncoding exon 1b.4,6 The P1- and P2-
expressed mRNAs have different 59 untranslated regions (UTRs) but an identical open reading frame (ORF) region and 39UTR. (D) The EGR2 (E1, E2, and E3)
and SOX10 (S1 and S2) binding sites of the P2 promoter region that function synergistically to regulate Cx32 expression in the nervous system. a Variants
included in this study. b Novel variants.
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GJB1. Previous in vitro analysis of the c.-146-
27T.C (c.-529T.C) mutation in the E3 region
or deletion of the S2 region have demonstrated a par-
tial loss of promoter activity.7,24 The indistinguishable
clinical phenotype of the patients included in this
study from patients with complete loss of function
mutations in GJB1 suggests that the noncoding mu-
tations described cause complete loss of function.
In this study, we describe 5 pathogenic mutations,
3 of which are novel, in noncoding regions of GJB1,
which are predicted to result in loss of function by
a combination of transcription factor binding, disrup-
tion of mRNA translation, and altered mRNA stabil-
ity. The search for these noncoding mutations was
largely driven by the recognition of the classical phe-
notype of CMTX1 in the absence of mutations in the
coding regions of GJB1. The large number of non-
coding mutations in GJB1 (11.4% of our cohort of
219 GJB1 patients) is of interest and highlights the
importance of mutations in noncoding DNA in
human disease and the need to include noncoding
regions of GJB1 in targeted inherited neuropathy
gene panels.
The study also raises the possibility that these
types of mutations may be a more frequent cause of
other inherited neurologic conditions than has been
previously appreciated including in the not infre-
quent situation where next-generation sequencing
identifies a heterozygous mutation for a gene known
to cause recessive disease. How frequent similar non-
coding mutations will be in other hereditary neurop-
athies and other inherited neurologic diseases has yet
to be determined.
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